Skip Navigation


Hum. Reprod. Advance Access originally published online on June 2, 2009
Human Reproduction 2009 24(9):2238-2243; doi:10.1093/humrep/dep196
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
24/9/2238    most recent
dep196v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sánchez-Serrano, M.
Right arrow Articles by Pellicer, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sánchez-Serrano, M.
Right arrow Articles by Pellicer, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation{dagger}

María Sánchez-Serrano1,2, Edurne Novella-Maestre1, Esther Roselló-Sastre3, Natalia Camarasa3, José Teruel4 and Antonio Pellicer1,2,5

1 Department of Obstetrics and Gynaecology, Hospital Universitario Dr Peset, Av Gaspar Aguilar 90, 46017 Valencia, Spain 2 Instituto Valenciano de Infertilidad (IVI)-Valencia, Valencia, Spain 3 Department of Pathology, Hospital Universitario Dr Peset, Valencia, Spain 4 IVI-Barcelona, Barcelona, Spain

5 Correspondence address. E-mail: pellicer_ant{at}gva.es

BACKGROUND: Breast cancer is a frequent indication for ovarian cortex cryopreservation due to its high incidence. The main concern of this procedure is the possibility of reintroducing metastatic cells within the implant, an issue that has not been addressed systematically. Thus, a study was designed to analyse the presence of ovarian metastases in breast cancer patients undergoing ovarian tissue cryopreservation.

METHODS: Morphological and immunohistochemical studies following the concept of the sentinel lymph node (SLN) were performed on 100 cortical ovarian biopsies obtained from 63 patients and on six frozen-thawed entire cortex from patients with the diagnosis of infiltrating ductal breast carcinoma undergoing ovarian cortex extraction and cryopreservation. The antibody panel included Cytokeratin CAM 5.2, Gross Cystic Disease Fluid Protein-15 (GCDFP15), Wilms' tumour antigen-1 (WT1) and Mammaglobin 1.

RESULTS: Employing only morphologic criteria, suspicious neoplastic cells were detected in five biopsies, but in none of the six entire cortex analysed. These five cases were reclassified as hyperplasic surface epithelium-inclusion cysts (CAM 5.2+, WT1+) or apoptotic granulosa cells (CAM 5.2–, GCDFP15+, WT1–).

CONCLUSIONS: Using the methodology of the SLN our data suggest the absence of tumour cells in biopsies obtained from patients undergoing ovarian cortex cryopreservation to preserve their fertility potential, although future methods of cancer screening may change our perception of this procedure.

Key words: ovarian cortex cryopreservation/breast cancer/ovarian metastases


{dagger} Presented in part at the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology Lyon, France, 1–4 July 2007.

Submitted on August 8, 2008; resubmitted on March 4, 2009; accepted on March 9, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.